Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2.

Breitkopf SB, Yang X, Begley MJ, Kulkarni M, Chiu YH, Turke AB, Lauriol J, Yuan M, Qi J, Engelman JA, Hong P, Kontaridis MI, Cantley LC, Perrimon N, Asara JM.

Sci Rep. 2016 Feb 3;6:20471. doi: 10.1038/srep20471.

2.

Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways.

Rothenberg SM, Concannon K, Cullen S, Boulay G, Turke AB, Faber AC, Lockerman EL, Rivera MN, Engelman JA, Maheswaran S, Haber DA.

Elife. 2015 Feb 16;4. doi: 10.7554/eLife.06132.

3.

MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors.

Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, Engelman JA.

Cancer Res. 2012 Jul 1;72(13):3228-37. doi: 10.1158/0008-5472.CAN-11-3747. Epub 2012 May 2.

4.

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, Engelman JA.

Cancer Discov. 2012 Mar;2(3):227-35. doi: 10.1158/2159-8290.CD-11-0341. Epub 2012 Jan 16.

5.

Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer.

Yang X, Turke AB, Qi J, Song Y, Rexer BN, Miller TW, Jänne PA, Arteaga CL, Cantley LC, Engelman JA, Asara JM.

Cancer Res. 2011 Sep 15;71(18):5965-75. doi: 10.1158/0008-5472.CAN-11-0445. Epub 2011 Jul 20.

6.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA.

Sci Transl Med. 2011 Mar 23;3(75):75ra26. doi: 10.1126/scitranslmed.3002003.

7.

PIKing the right patient.

Turke AB, Engelman JA.

Clin Cancer Res. 2010 Jul 15;16(14):3523-5. doi: 10.1158/1078-0432.CCR-10-1201. Epub 2010 Jun 10.

8.

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA.

Cancer Cell. 2010 Jan 19;17(1):77-88. doi: 10.1016/j.ccr.2009.11.022.

Supplemental Content

Loading ...
Support Center